Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.

Abstract

INTRODUCTION:

As a result of the approval of several immune checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC), many older adults are being treated with ICIs. Older adults are underrepresented in most pharmaceutical clinical trials. Therapy outcomes in this population with ICIs is particularly important since, age related factors may have an influence on the immune system.

METHODS:

We utilized the MD Anderson Cancer Center Gemini Team's Lung Cancer Database to retrospectively study patients ≥70 years of age with advanced NSCLC treated with anti-PD-(L)1 monotherapy to look at the clinical outcomes.

RESULTS:

179 patients met the inclusion criteria for this retrospective analysis. There were 106 men and 73 women. The median age of the cohort was 74.9 years, and overall survival was 20.6 months. 27.6% of all patients had an objective response to therapy. In 33 patients who had radiological progression, treatment continued beyond progression due to clinical benefit. In this group, 6 patients had subsequent improvement in radiologic assessment. Age groups were not significantly associated with differences in clinical outcomes.

CONCLUSIONS:

This study suggests that anti-PD-(L)1 monotherapy is effective and well tolerated among older adults with advanced NSCLC. While pseudoprogression is rare, treatment beyond progression may provide clinical benefit in a subset of patients and warrants further investigation.

• Authors: Mehmet Altan, Eric K Singhi, Michelle Worst, Brett W Carter, Cheuk H Leung, J Jack Lee, Carolyn J Presley, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jianjun Zhang, Don L Gibbons, Ara A Vaporciyan, John V Heymach, Frank E Mott
• Journal: Clinical lung cancer (Clin Lung Cancer) Vol. 23 Issue 3 Pg. 236-243 (05 2022) ISSN: 1938-0690 [Electronic] United States
• PMID: 35216923 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• B7-H1 Antigen

Topics

• Aged
• B7-H1 Antigen
• Carcinoma, Non-Small-Cell Lung
• Female
• Humans
• Lung Neoplasms
• Male
• Retrospective Studies
• Treatment Outcome